Logistics Live: Conversations & Insights on the Global Supply Chain Quick Group of Companies

Medical care and scientific research offer some of the most challenging – and developing – areas for global supply chain logistics. And few are more significant– in terms of potential for improving human life and logistics precision required – than Cell & Gene Therapy or CGT.
These CGT “medical miracles” bring logistics opportunities and challenges, around timing, temperature, chain of identity, synchronization, integration, scale, back up planning, and more.
So, what is required – logistically – to help ensure CGT clinical trials and personalized therapies get handled safely, securely, and on time?
QuickSTAT's Global Head of Strategy for CGT and DTP, Mike Sweeney and Senior VP of Commercial Operations Scott Ohanesian explain. 
For more information on clinical trial logistics, visit our website at quickstat.com.

In Part 2, Mike Sweeney, QuickSTAT’s Global Head of Strategy for CGT and Direct to Patient products, offers specific supply chain design ideas and tactics to establish processes and overcome potential logistics roadblocks. He breaks down extraordinary case studies, and gives his views on what’s next – particularly around regulation.

Critically ill patients increasingly can participate in life saving and life changing cell & gene therapy clinical trials without having to leave their homes with the Direct- to -Patient and Direct- from -Patient model. So how do you set up these supply chains? How do you mitigate risk? And how do you ensure they’re resilient? Mike Sweeney, QuickSTAT’s Global Head of Strategy for CGT and Direct to Patient products, explains.